A Phase 3, Multicentre, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors
This is a Phase 3, multicentre, randomized, double blind, placebo-controlled study
evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in
subjects with relapsed or refractory multiple myeloma who are considered sensitive or naïve
to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society